Eylea is a new anti growth factor agent injected into the vitreous cavity in the same way as Lucentis. Recent trials have shown Eylea to be as effective as Lucentis in the treatment of age related macular degeneration but with the advantage of only requiring review and re treatment every 2 months.
For further information on this new development please follow link below.
Disclaimer : The information provided in this website is intended as a useful aid to general practitioners, optometrists and patients. It is impossible to diagnose and treat patients adequately without a thorough eye examination by a qualified ophthalmologist, optometrist or your general practitioner. Hopefully the information will be of use prior to and following a consultation which it supplements and does not replace.